Portal Biotechnologies, a Cambridge, MA-based cell engineering platform company, raised $7M in Seed funding.
The round was led by IA Ventures with participation from Pear VC, Undeterred Ventures, Page One VC, IKJ Capital and other current investors.
The company intends to use the funds to drive its continued growth and the launch of new products.
Led by CEO and Founder Armon Sharei, Portal is a cell engineering platform company focused on enabling new cell engineering and analytics across research and clinical applications. The company is implementing an approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and molecular design technologies. Its initial product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types. The process relies on transient perturbation of a cell’s membrane as it transits through microscopic holes in a thin, specially designed, silicon surface. The technology’s ability to be used stand-alone or as an integrated component of third-party systems provides a significant opportunity to broadly impact the fields of biological research and cellular therapeutics.
